In vivo evaluation of a novel pH- and time-based multiunit colonic drug delivery system

被引:37
作者
Bott, C
Rudolph, MW
Schneider, ARJ
Schirrmacher, S
Skalsky, B
Petereit, HU
Langguth, P
Dressman, JB
Stein, J [1 ]
机构
[1] Goethe Univ Frankfurt, Dept Med 2, D-6000 Frankfurt, Germany
[2] Rohm GmbH, Pharma Polymers, Darmstadt, Germany
[3] Johannes Gutenberg Univ Mainz, Inst Pharm, D-6500 Mainz, Germany
[4] Goethe Univ Frankfurt, Inst Pharmaceut Technol, D-6000 Frankfurt, Germany
关键词
D O I
10.1111/j.1365-2036.2004.02033.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Targeted drug delivery to the colon is important for topical treatment of inflammatory bowel diseases. Established targeting systems predominantly focus on either pH- or time-dependent release, or bacterial degradation. Aim: To perform a three-phase, crossover design trial evaluating a novel combined pH- and time-based multiunit delivery system. Methods: Twelve healthy male volunteers each received 200 mg of caffeine as either uncoated immediate release tablets, coated pellets with pH-dependent rapid release (EUDRAGIT FS 30D), and pellets with pH- and time-based release (inner layer EUDRAGIT RL/RS 30D; outer layer EUDRAGIT FS 30D). Orocecal transit time was measured using lactose-[C-13]ureide. Serum concentrations of caffeine were measured by high-performance liquid chromatography. Results: In contrast to the uncoated tablet, both coated systems reached the ileocecal region almost at the same time (3.19 +/- 0.71 and 3.33 +/- 0.81 h). Serum caffeine profiles were significantly prolonged for the pH and time delivery system compared with the pH-only based system (median t(max) 12.0 vs. 5.5 h; P < 0.001). This was further reflected by a lower C-max value and a lower area under the curve within 24 h after application. Conclusion: Compared with the conventional delivery systems, drug release from the new dosage form may offer a new dimension for the oral treatment of mid to distal ulcerative colitis.
引用
收藏
页码:347 / 353
页数:7
相关论文
共 23 条
[1]   TARGETING DRUGS TO THE COLON - DELIVERY SYSTEMS FOR ORAL-ADMINISTRATION [J].
ASHFORD, M ;
FELL, JT .
JOURNAL OF DRUG TARGETING, 1994, 2 (03) :241-257
[2]   Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables [J].
Camma, C ;
Giunta, M ;
Rosselli, M ;
Cottone, M .
GASTROENTEROLOGY, 1997, 113 (05) :1465-1473
[3]   Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease [J].
Ewe, K ;
Schwartz, S ;
Petersen, S ;
Press, AG .
DIGESTIVE DISEASES AND SCIENCES, 1999, 44 (07) :1434-1439
[4]   Use of novel solid-phase extraction sorbent materials for high-performance liquid chromatography quantitation of caffeine metabolism products methylxanthines and methyluric acids in samples of biological origin [J].
Georga, KA ;
Samanidou, VF ;
Papadoyannis, IN .
JOURNAL OF CHROMATOGRAPHY B, 2001, 759 (02) :209-218
[5]  
Geypens B, 1999, J NUCL MED, V40, P1451
[6]   A novel pH- and time-based multi-unit potential colonic drug delivery system. I. Development [J].
Gupta, VK ;
Beckert, TE ;
Price, JC .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 213 (1-2) :83-91
[7]   A novel pH- and time-based multi-unit potential colonic drug delivery system. II. Optimization of multiple response variables [J].
Gupta, VK ;
Assmus, MW ;
Beckert, TE ;
Price, JC .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 213 (1-2) :93-102
[8]  
Hebden JM, 2000, ALIMENT PHARM THER, V14, P155
[9]  
KLEIN S, 2002, DTSCH APOTHEKER ZEIT, V142, P3404
[10]  
MAYER EA, 1994, PHYSL GASTROINTESTIN, P903